In the phase 2 trial HYPORT-STS conducted at MD Anderson Cancer Center, moderately hypofractionated preoperative radiotherapy to patients with soft...

In the IMmotion 010 study presented by Dr. Axel Bex, atezolizumab (anti-PD-L1) monotherapy was studied as adjuvant therapy in patients...

In IPSOS trial Presented by Dr. Siow Ming Lee, 1L #atezolizumab significantly improved OS vs single-agent chemo in platinum-ineligible pts...

In the Japanese JCOG0905 study presented by Dr. Hiroaki Hiraga, adding Ifosfamide (IF) to adjuvant chemotherapy in high grade osteosarcoma...

In the randomized KEYLYNK-010 study presented by Dr. Evan Yu, #Pembrolizumab + #olaparib (P+O) failed to improve rPFS or OS...

First-line #pembrolizumab monotherapy continued to show durable superiority over chemotherapy after 5 years of follow-up in #PD-L1–positive, locally advanced/metastatic NSCLC...

In the phase III #KEYNOTE-716 trial published in the Lancet, Adjuvant #pembrolizumab improved the clinical outcomes compared to placebo in...

In the phase III LEAP-002 study presented by Richard Finn, adding pembrolizumab to first line #Lenvatinib in HCC patients improved...

A locally applied, silicone-based polyurethane film dressing (Mepitel Film) can reduce #radiation induced skin toxicities in #breast_cancer patients. According a...

In multicenter, phase 3 #MITNEC-A1 study, 18F-sodium fluoride PET–CT was compared to 99mTc bone scintigraphy with SPECT in patients with...